A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats

Aarts, Frits; Hendriks, T.; Boerman, Otto C.; Koppe, Manuel J.; Oyen, Wim J.G.; Bleichrodt, Robert P.

doi:10.1245/s10434-007-9509-2

Cited by 42 publications

(40 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies on rodents have shown that radioimmunotherapy (RIT) is an efficient adjuvant after cytoreductive surgery for peritoneal carcinomatosis (7)(8)(9). Several IP RIT studies using strong b-or a-emitters are ongoing in animals (8)(9)(10)(11)(12)(13).…”

mentioning

confidence: 99%

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies

et al. 2010

View full text Add to dashboard Cite

We assessed the efficiency and toxicity of brief intraperitoneal radioimmunotherapy using high activities of 125 I-labeled monoclonal antibody (mAb) in the treatment of small-volume peritoneal carcinomatosis. Methods: Brief intraperitoneal radioimmunotherapy consisted of a 185-MBq (740 MBq/mg) intraperitoneal injection of 125 I-35A7 (an anti-carcinoembryonic antigen mAb) into athymic nude mice 4 d after peritoneal tumor xenografting and, after 1 h, abundant washing of the peritoneal cavity with saline solution to remove unbound radioactivity. Another group of mice received this treatment plus a 37-MBq intravenous injection of 125 I-35A7 on day 7 or 11 after grafting. Control groups received a brief treatment followed by an additional intravenous injection on day 7 of either saline solution or irrelevant 125 I-PX. Tumor growth was monitored by bioluminescence imaging and SPECT/CT, and hematologic toxicity was evaluated by complete blood counts. Survival time was reported, and the mice were sacrificed when the bioluminescence signal reached 4.5 · 10 7 photons/s. The biodistribution of 125 I-35A7 mAb after intravenous or brief treatment was assessed, and the mean absorbed irradiation dose by organs and tumors was calculated using the MIRD formalism. Results: Mild, transient hematologic toxicity was observed after the brief treatment plus intravenous 125 I-mAb, with no weight loss. Median survival increased from 32 d in the control groups, to 46 d in the brief treatment group, to 66 d in the group additionally receiving intravenous treatment on day 11, to 73 d in the group additionally receiving intravenous treatment on day 7. The brief treatment alone resulted in a 3-fold higher tumor-toblood uptake ratio than did the standard intravenous treatment, and the mean absorbed irradiation doses by tumors were 11.6 Gy for the brief treatment and 16.7 Gy for the additional intravenous treatment. For healthy tissues other than blood, the mean absorbed irradiation dose did not exceed 1 Gy after brief treatment and 4.2 Gy after intravenous treatment. Conclusion: The efficiency, low toxicity, and high tumor-to-healthy tissue uptake ratio associated with brief intraperitoneal 125 I-35A7 radioimmunotherapy suggest that this method can be used in combination with radiation-synergistic drugs in the therapy of smallvolume peritoneal carcinomatosis after cytoreductive surgery.

show abstract

mentioning

confidence: 99%

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In a model with resected peritoneal carcinomatosis, the 177 Lu-MG1 antibody improved survival after cytoreductive surgery as compared to chemotherapy. 44, 45 Koppe et al also demonstrated the efficacy of RIT in peritoneal carcinomatosis after cytoreductive surgery. 49 In these studies, rats were first injected intraperitoneally with 2 · 10 6 CC-531 cells and tumors were allowed to grow for 14 days.…”

Section: Impact Of A-particles On the Peritoneummentioning

confidence: 98%

“…However, several recent studies have modeled minimal residual and metastatic disease in rat and mouse models and evaluated the efficacy of RIT. [38][39][40][41][42][43][44][45] Some of the models of minimal disease and the RIT strategies employed in these studies are schematically described in Figure 1.…”

Section: Impact Of A-particles On the Peritoneummentioning

confidence: 99%

Emerging Trends for Radioimmunotherapy in Solid Tumors

Jain

Gupta

Kaur

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. Poor tumor uptake and undesirable pharmacokinetics, however, have precluded the administration of radioimmunoconjugates at therapeutically relevant doses thereby limiting the clinical utility of RIT. In solid tumors, efficacy of RIT is further compromised by heterogeneities in blood flow, tumor stroma, expression of target antigens and radioresistance. As a result significant efforts have been invested toward developing strategies to overcome these impediments. Further, there is an emerging interest in exploiting shortrange, high energy a-particle emitting radionuclides for the eradication of minimal residual and micrometastatic disease. As a result several modalities for localized therapy and models of minimal disease have been developed for preclinical evaluation. This review provides a brief update on the recent efforts toward improving the efficacy of RIT for solid tumors, and development of RIT strategies for minimal disease associated with solid tumors. Further, some of promising approaches to improve tumor targeting, which showed promise in the past, but have now been ignored are also discussed.

show abstract

“…6,9 The peritoneal perfusate consisting of 250 mL NaCl (0.9%) was warmed to 41.5°C and infused into the abdomen at 10 mL/min during 90 min. Mitomycin-C (Nycomed Christiaens BV, Breda, The Netherlands) was dissolved in saline and added to the perfusate in three separate gifts at 30 min intervals, each containing 50%, 25%, and 25% of the total dose of 35 mg/m peritoneal cavity.…”

Section: Hipecmentioning

confidence: 99%

Intraoperative versus Early Postoperative Intraperitoneal Chemotherapy after Cytoreduction for Colorectal Peritoneal Carcinomatosis: an Experimental Study

et al. 2011

View full text Add to dashboard Cite

Background. Perioperative intraperitoneal chemotherapy is used as an adjunct to cytoreductive surgery (CS) for peritoneal carcinomatosis (PC) in order to prolong survival. Worldwide, hyperthermic intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC), and combinations of the two are used. It remains unclear which regimen is most beneficial. Methods. The rat colon carcinoma cell line CC-531 was injected into the peritoneal cavity of 80 WAG/Rij rats to induce PC. Animals were randomized into four treatment groups (n = 20): CS only, CS followed by HIPEC (mitomycin 35 mg/m 2 at 41.5°C), CS followed by EPIC during 5 days (i.p. injection of mitomycin on day 1 and 5-fluorouracil on days 2-5), and CS followed by HIPEC plus EPIC. Primary outcome was survival. Results. In rats treated with CS only, median survival was 53 days (95% confidence interval (CI) 49-57 days). In rats treated with CS followed by HIPEC, survival was significantly (P = 0.001) increased (median survival 94 days, 95% CI 51-137 days). In the group treated with EPIC after CS, 12 out of 20 rats were still alive at the end of the experiment (P \ 0.001 as compared with CS only). In the group receiving both treatments, 11 rats died of toxicity, and therefore this group was not included in the survival analysis.Conclusions. Both EPIC and HIPEC were effective in prolonging survival. The beneficial effect of EPIC on survival seemed to be more pronounced than that of HIPEC.Further research is indicated to evaluate and compare the possible benefits and adverse effects associated with both treatments.

show abstract

A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats

Cited by 42 publications

References 25 publications

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies

Emerging Trends for Radioimmunotherapy in Solid Tumors

Intraoperative versus Early Postoperative Intraperitoneal Chemotherapy after Cytoreduction for Colorectal Peritoneal Carcinomatosis: an Experimental Study

Contact Info

Product

Resources

About

A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats

Cited by 42 publications

References 25 publications

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies

Emerging Trends for Radioimmunotherapy in Solid Tumors

Intraoperative versus Early Postoperative Intraperitoneal Chemotherapy after Cytoreduction for Colorectal Peritoneal Carcinomatosis: an Experimental Study

Contact Info

Product

Resources

About

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies

Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing ¹²⁵I-Labeled Monoclonal Antibodies